TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03065387
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03065387
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02656212
Drug: epicatechin
Normalized name: EPICATECHIN
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg (+)-epicatechin, taken orally, one pill/day in the morning
Study: NCT01995006
Drug: metamizole
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: metamizol tablets (500mg): 1000mg TID during 7 days
Study: NCT01655108
Drug: Minoxidil
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
Study: NCT01655108
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
Study: NCT02598557
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00838214
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg capsule, 3x per day for 6 months
Study: NCT00838214
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
Study: NCT00908583
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive bortezomib as described in protocol
Study: NCT00908583
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive rituximab as described in protocol
Study: NCT00908583
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
Study: NCT01096212
Drug: original sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
Study: NCT01096212
Drug: generic sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
Study: NCT02072434
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Edoxaban 30 mg tablets for oral administration
Study: NCT02072434
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin tablet, 1.0 or 2.5 mg, for oral administration
Study: NCT02072434
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin per label, at prescribed dose until PT INR at least 2.0
Study: NCT00625703
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid.
Study: NCT04447612
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy
Study: NCT04447612
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles
Study: NCT04447612
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
Study: NCT00984568
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ASA administered orally at a dose of 2 g/day.
Study: NCT00867126
Drug: pioglitazone hydrochloride
Normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03385655
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
Study: NCT03385655
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg once daily, orally.
Study: NCT03385655
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600mg twice daily, orally.
Study: NCT03385655
Drug: CFI-400945
Normalized name: Cfi-400945 free base
DrugBank: Ocifisertib (DB18746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
Study: NCT03385655
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg daily 3 weeks on, 1 week off
Study: NCT03385655
Drug: Durvalumab and Tremelimumab
Normalized name: tremelimumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
Study: NCT03385655
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 IV 60min Day 1 q 21 days
Study: NCT04061928
Drug: PD-1
Normalized name: NPD-1
DrugBank: PD-168393 (DB07662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
Study: NCT00902395
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 1.0 mg/kg (maximum 20 mg)
Study: NCT01025492
Drug: Trilipix
Normalized name: Trilipix
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg po daily
Study: NCT02809742
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
Study: NCT01726452
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
Study: NCT00003981
Drug: indisulam
Normalized name: Indisulam
DrugBank: Indisulam (DB06370)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00902395
Drug: Midazolam, ketamine
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
Study: NCT01213667
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: upload (three monthly injections), re-treatment as needed
Study: NCT01726452
Drug: Cisplatin / Oxaliplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
Study: NCT01726452
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
Study: NCT01726452
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
Study: NCT01726452
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
Study: NCT01726452
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m², day 1 of each cycle (i.e. every 14 days)
Study: NCT01489696
Drug: mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01489696
Drug: tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02253758
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol will be injected as a continuous infusion by TCI intravenously
Study: NCT03618641
Drug: CMP-001
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
Study: NCT00405210
Drug: sorafenib (200 or 400mg bid) and taxotere iv
Normalized name: sorafenib 200 MG
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
Study: NCT01498900
Drug: repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescription according to the product labelling at the physicians' discretion
Study: NCT01726452
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
Study: NCT03422822
Drug: Abrocitinib 100 mg
Normalized name: abrocitinib 100 MG
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
Study: NCT03422822
Drug: Abrocitinib 200 mg
Normalized name: abrocitinib 200 MG
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
Study: NCT03422822
Drug: Abrocitinib 100 mg
Normalized name: abrocitinib 100 MG
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
Study: NCT03422822
Drug: Abrocitinib 100 mg
Normalized name: abrocitinib 100 MG
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
Study: NCT03422822
Drug: Abrocitinib 200 mg
Normalized name: abrocitinib 200 MG
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
Study: NCT04088734
Drug: ABO-102
Normalized name: ABO-102
DrugBank: Rebisufligene etisparvovec (DB16784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10\^13 vg/kg
Study: NCT02964507
Drug: GSK525762
Normalized name: Bet inhibitor gsk525762
DrugBank: Molibresib (DB16239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK525762 will be administered.
Study: NCT02964507
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant will be administered.
Study: NCT04558463
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug
Study: NCT04558463
Drug: Oseltamivir 75mg
Normalized name: oseltamivir 75 MG
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug
Study: NCT00704080
Drug: XL765 (SAR245409)
Normalized name: XL765
DrugBank: XL765 (DB05241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
Study: NCT00704080
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
Study: NCT02391805
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir will be administered as per local labeling.
Study: NCT02391805
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir will be administered as per local labeling.
Study: NCT01431300
Drug: gadofosveset
Normalized name: Gadofosveset
DrugBank: Gadofosveset trisodium (DB06705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of the specified dosage of gadolinium contrast agent
Study: NCT04163523
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03235531
Drug: Valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
Study: NCT03235531
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
Study: NCT01225315
Drug: Setipiprant
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
Study: NCT01905423
Drug: Albendazole (annual)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400 mg pnce annually
Study: NCT01905423
Drug: Diethylcarbamazine (annual)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine 6 mg/kg once annually
Study: NCT04622618
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticonvulsant, Antiemetic, Analgesic
Study: NCT01905423
Drug: Albendazole (semiannual)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400 mg twice annually
Study: NCT01905423
Drug: Diethylcarbamazine (semiannual)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine 6 mg/kg twice annually
Study: NCT00537901
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy
Study: NCT04572516
Drug: BTX A Topical
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
Study: NCT04572516
Drug: BTX A Injection
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
Study: NCT02905318
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg orally on days 1-21 each 28 day cycle
Study: NCT02684669
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active drug infusion
Study: NCT00393770
Drug: L-acetylcarnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-500 mg/kg/die.
Study: NCT02624349
Drug: Quadravalent human papillomavirus vaccine
Normalized name: human papillomavirus
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
Study: NCT02716012
Drug: MTL-CEBPA
Normalized name: MTL-CEBPA
DrugBank: MTL-CEBPA (DB18143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT02716012
Drug: Sorafenib 200mg
Normalized name: SORAFENIB 200MG TAB
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib tablets
Study: NCT03506373
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03506373
Drug: Ixazomib Citrate
Normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00962156
Drug: Ringers acetate
Normalized name: Mimulus ringens whole extract
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion for volume expansion in the ICU
Study: NCT04048278
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
Study: NCT02044965
Drug: Probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
Study: NCT00247130
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00247130
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04428502
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT01262352
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg tablet, oral use, twice daily every 12 hours (q12h)
Study: NCT02235727
Drug: GBR 900
Normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02036554
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study: NCT02036554
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study: NCT02447705
Drug: telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: telbivudine replace Lamivudine
Study: NCT01145014
Drug: BI 660848
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral drinking solution
Study: NCT01145014
Drug: BI 660848
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral drinking solution